Patsnap, a global leader in innovation and pharma intelligence, announced the launch of Hiro Life Sciences (Hiro LS), a groundbreaking AI assistant poised to redefine biopharmaceutical research and accelerate the path to life-saving therapies.  

Powered by PharmaGPT, Patsnap’s pharmaceutical-trained large language model (LLM), Hiro LS integrates advanced generative AI capabilities with domain-specific intelligence to transform how biopharma teams access, analyze, and act on critical data. By equipping users with an intuitive assistant tailored to their R&D and innovation needs, Hiro LS eliminates bottlenecks in drug discovery workflows and empowers researchers to drive breakthroughs with speed, precision, and confidence. 

“Biopharma teams face immense pressure to innovate rapidly and cost-effectively,” said Haydn Evans, Senior GTM Director at Patsnap. “With Hiro LS, we’ve created a secure and intuitive AI assistant that bridges the gap between data, AI, and discovery, enabling researchers to focus on what matters most—delivering breakthrough therapies to patients faster than ever before.” 

Unlike general-purpose LLMs, which often lack the specificity and depth required for pharmaceutical research, Hiro LS is specifically trained on both proprietary and external scientific datasets, including peer-reviewed articles, patents, drug data, clinical trials, sequence data, chemical structures, experimental data, and more. Proven to outperform general-purpose LLMs in standardized pharmaceutical exams, Hiro LS applies its robust knowledge to accurately interpret scientific queries and generate comprehensive, evidence-based answers, complete with links to original sources for full transparency. 

By seamlessly integrating with Patsnap’s robust ecosystem of proprietary life sciences intelligence solutions, Hiro LS empowers biopharma professionals with rapid, real-time analysis and deep exploration of critical areas such as scientific research, drug pipelines, clinical progress, regulatory policies, market insights, and more. Leveraging advanced techniques like retrieval-augmented generation (RAG) and reinforcement learning with human feedback (RLHF), Hiro LS continuously enhances the accuracy and relevance of its responses for real-world applications. This innovative approach allows researchers to reclaim valuable time, enabling them to focus on advancing their discoveries and driving meaningful breakthroughs. 

Hiro LS redefines how researchers interact with data by offering:

• Real-Time Insights: From competitor drug pipelines to regulatory guidelines, Hiro LS delivers precise, actionable answers with full source transparency. 

• Seamless Integration: Leverage Hiro LS as a standalone solution, an in-product assistant, or embed its underlying LLM into proprietary systems via APIs for tailored workflows. 

• Enhanced Collaboration: Share structured research reports and data visualizations to accelerate decision-making across teams. 

• Secure Interactions: Ensure personal data remains private and is never used to train the AI. 

“With Hiro LS, we’ve developed a solution that is focused on streamlining pharmaceutical research,” said Haydn Evans, Senior GTM Director at Patsnap. “By combining generative AI with proprietary data, we’re enabling faster, smarter decision making and reducing the time to market for life-saving therapies.” 

In addition to being offered as a standalone solution, Hiro LS is available as an integrated assistant within Patsnap’s Life Sciences Intelligence platform. PharmaGPT, Hiro LS’s underlying LLM, can also be integrated into private enterprise data systems through APIs to enhance connectivity of disparate systems and scale existing workflows. 

“This launch marks a pivotal step in Patsnap’s mission to democratize access to high quality data with AI,” added Evans. “With Hiro LS, we’re not just enhancing productivity; we’re helping our users shape the future of drug development.” 

Learn more or start your free trial of Hiro LS at www.patsnap.com/ai/ls.